AP NEWS
Click to copy
Press release content from BusinessWire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Asia-Pacific $100+ Mn Nonalcoholic Steatohepatitis Therapeutics Markets to 2024 - ResearchAndMarkets.com

January 16, 2019

DUBLIN--(BUSINESS WIRE)--Jan 16, 2019--The “Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market” report has been added to ResearchAndMarkets.com’s offering.

The NASH Asia-Pacific market will be valued at $102.6m in 2024, growing from $33.7m in 2017 at a CAGR of 17.2%.

Over the forecast period the prevalence of Non-Alcoholic Steato-Hepatitis (NASH) is expected to increase significantly across the APAC markets, in parallel with the increasing prevalence of associated risk factors such as obesity, type II diabetes (T2D), dyslipidemia and other metabolic conditions.

NAFLD has become the most common liver disease worldwide. Global prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) is estimated at 24%; the highest rates are in South America and the Middle East, followed by the US and Europe. Non-Alcoholic Fatty Liver Disease (NAFLD) is also an emerging problem in the Asia-Pacific region, where it is likely to increase in the future.

Currently, the prevalence population of Non-Alcoholic Fatty Liver Disease (NAFLD) in Asia is around 25%, like many Western countries. Non-Alcoholic Steato-Hepatitis (NASH) is present in at least 20% of obese adults or children and in at least 5% of those who are overweight. The prevalence of Non-Alcoholic Steato-Hepatitis (NASH) in biopsy-proven Non-Alcoholic Fatty Liver Disease (NAFLD) patients is 63.5% in Asia.

The rising prevalence population, together with the significant diagnostic advancements using ultrasound and biomarkers, improving health awareness, and increasing affordability and healthcare access, will increase diagnosis and the treatment-receiving population, driving demand and contributing to market growth.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Marketed Products

4 Pipeline Analysis

5 Clinical Trial Analysis

6 Multi-scenario Forecast

7 Drivers and Barriers

8 Deals and Strategic Consolidations

9 Appendix

Companies Mentioned

Allergan Galmed Genfit Gilead Intercept Pharmaceuticals Zydus

For more information about this report visit https://www.researchandmarkets.com/research/sxtc43/asiapacific?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190116005287/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs

KEYWORD: ASIA PACIFIC

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/16/2019 03:40 AM/DISC: 01/16/2019 03:40 AM

http://www.businesswire.com/news/home/20190116005287/en

All contents © copyright 2019 The Associated Press. All rights reserved.